John B Kisiel

List of Publications by Year in descending order

102 papers	2,513 citations	186209 28 h-index	223716 46 g-index
105 all docs	105 docs citations	105 times ranked	3348 citing authors

#	Article	IF	Citations
1	Screening for esophageal squamous cell carcinoma: recent advances. Gastrointestinal Endoscopy, 2018, 88, 413-426.	0.5	186
2	Hepatocellular Carcinoma Detection by Plasma Methylated DNA: Discovery, Phase I Pilot, and Phase II Clinical Validation. Hepatology, 2019, 69, 1180-1192.	3.6	138
3	Stool DNA testing for the detection of pancreatic cancer. Cancer, 2012, 118, 2623-2631.	2.0	110
4	New DNA Methylation Markers for Pancreatic Cancer: Discovery, Tissue Validation, and Pilot Testing in Pancreatic Juice. Clinical Cancer Research, 2015, 21, 4473-4481.	3.2	108
5	Fecal Metabolomic Signatures in Colorectal Adenoma Patients Are Associated with Gut Microbiota and Early Events of Colorectal Cancer Pathogenesis. MBio, 2020, 11, .	1.8	101
6	Molecular markers for colorectal cancer screening. Gut, 2015, 64, 1485-1494.	6.1	100
7	Detection rate and outcome of colonic serrated epithelial changes in patients with ulcerative colitis or Crohn's colitis. Alimentary Pharmacology and Therapeutics, 2014, 39, 1408-1417.	1.9	79
8	Endoscopic overestimation of colorectal polyp size. Gastrointestinal Endoscopy, 2016, 83, 201-208.	0.5	74
9	A Novel Blood-Based Panel of Methylated DNA and Protein Markers for Detection of Early-Stage Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2021, 19, 2597-2605.e4.	2.4	73
10	Outcome of Sporadic Adenomas and Adenoma-Like Dysplasia in Patients with Ulcerative Colitis Undergoing PolypectomyÂ§â€. Inflammatory Bowel Diseases, 2012, 18, 226-235.	0.9	67
11	Identification of Prognostic Phenotypes of Esophageal Adenocarcinoma in 2 Independent Cohorts. Gastroenterology, 2018, 155, 1720-1728.e4.	0.6	67
12	Cytomegalovirus Infection of the Ileoanal Pouch. Inflammatory Bowel Diseases, 2013, 19, 2394-2399.	0.9	66
13	Stool <scp>DNA</scp> testing for the detection of colorectal neoplasia in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2013, 37, 546-554.	1.9	65
14	Validation of a Novel Multitarget Blood Test Shows High Sensitivity to Detect Early Stage Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2022, 20, 173-182.e7.	2.4	62
15	Combination Biologic Therapy in Inflammatory Bowel Disease: Experience From a Tertiary Care Center. Clinical Gastroenterology and Hepatology, 2021, 19, 616-617.	2.4	58
16	Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. Hepatology, 2018, 68, 78-88.	3.6	45
17	Detection of Gastric Cancer with Novel Methylated DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma. Clinical Cancer Research, 2018, 24, 5724-5734.	3.2	43
18	Novel Methylated DNA Markers Discriminate Advanced Neoplasia in Pancreatic Cysts: Marker Discovery, Tissue Validation, and Cyst Fluid Testing. American Journal of Gastroenterology, 2019, 114, 1539-1549.	0.2	43

#	Article	IF	Citations
19	Multitarget stool DNA test: clinical performance and impactÂonÂyield and quality of colonoscopy for colorectal cancer screening. Gastrointestinal Endoscopy, 2017, 85, 657-665.e1.	0.5	40
20	Methylated DNA in Pancreatic Juice Distinguishes Patients With Pancreatic Cancer From Controls. Clinical Gastroenterology and Hepatology, 2020, 18, 676-683.e3.	2.4	40
21	Incremental diagnostic yield of chromoendoscopy and outcomes in inflammatory bowel disease patients with a history of colorectal dysplasia on white-light endoscopy. Gastrointestinal Endoscopy, 2016, 83, 1005-1012.	0.5	39
22	Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study. Clinical Gastroenterology and Hepatology, 2022, 20, e508-e528.	2.4	36
23	Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 914-921.e5.	2.4	35
24	Discovery, Validation, and Application of Novel Methylated DNA Markers for Detection of Esophageal Cancer in Plasma. Clinical Cancer Research, 2019, 25, 7396-7404.	3.2	33
25	Clinical Benefit of Capsule Endoscopy in Crohnâ€™s Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Inflammatory Bowel Diseases, 2018, 24, 1582-1588.	0.9	31
26	A Comprehensive Approach to Sequence-oriented IsomiR annotation (CASMIR): demonstration with IsomiR profiling in colorectal neoplasia. BMC Genomics, 2018, 19, 401.	1.2	31
27	Long-term Follow-up of Patients Having False-Positive Multitarget Stool DNA Tests after Negative Screening Colonoscopy: The LONG-HAUL Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 614-621.	1.1	29
28	Novel Approach to Fecal Occult Blood Testing by Assay of Erythrocyte-Specific microRNA Markers. Digestive Diseases and Sciences, 2017, 62, 1985-1994.	1.1	29
29	Accurate Nonendoscopic Detection of Barrett's Esophagus by Methylated DNA Markers: A Multisite Case Control Study. American Journal of Gastroenterology, 2020, 115, 1201-1209.	0.2	28
30	DNA Methylation and Mutation of Small Colonic Neoplasms in Ulcerative Colitis and CrohnÊ¼s Colitis. Inflammatory Bowel Diseases, 2016, 22, 1559-1567.	0.9	27
31	Bariatric Surgery Is Acceptably Safe in Obese Inflammatory Bowel Disease Patients: Analysis of the Nationwide Inpatient Sample. Obesity Surgery, 2018, 28, 1007-1014.	1.1	27
32	Circulating Tumor DNA and Hepatocellular Carcinoma. Seminars in Liver Disease, 2019, 39, 452-462.	1.8	27
33	Using cell-free DNA for HCC surveillance and prognosis. JHEP Reports, 2021, 3, 100304.	2.6	27
34	Outcomes of Endoscopic Therapy for Luminal Strictures in Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2018, 24, 1575-1581.	0.9	26
35	Specificity of the Multi-Target Stool DNA Test for Colorectal Cancer Screening in Average-Risk 45â€“49 Year-Olds: A Cross-Sectional Study. Cancer Prevention Research, 2021, 14, 489-496.	0.7	26
36	Combining copy number, methylation markers, and mutations as a panel for endometrial cancer detection via intravaginal tampon collection. Gynecologic Oncology, 2020, 156, 387-392.	0.6	22

#	Article	IF	Citations
37	Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance. Current Treatment Options in Gastroenterology, 2020, 18, 109-119.	0.3	21
38	Stool Methylated DNA Markers Decrease Following Colorectal Cancer Resectionâ€"Implications for Surveillance. Digestive Diseases and Sciences, 2014, 59, 1764-1767.	1.1	18
39	Low Incidence of Aerodigestive Cancers in Patients With Negative Results From Colonoscopies, Regardless of Findings From Multitarget Stool DNA Tests. Clinical Gastroenterology and Hepatology, 2020, 18, 864-871.	2.4	18
40	Comparative Cost Effectiveness of Reflux-Based and Reflux-Independent Strategies for Barrett's Esophagus Screening. American Journal of Gastroenterology, 2021, 116, 1620-1631.	0.2	18
41	Multitarget Stool DNA Screening in Clinical Practice: High Positive Predictive Value for Colorectal Neoplasia Regardless of Exposure to Previous Colonoscopy. American Journal of Gastroenterology, 2020, 115, 608-615.	0.2	17
42	Novel Methylated DNA Markers in the Surveillance of Colorectal Cancer Recurrence. Clinical Cancer Research, 2021, 27, 141-149.	3.2	17
43	High Detection Rates of Pancreatic Cancer Across Stages by Plasma Assay of Novel Methylated DNA Markers and CA19-9. Clinical Cancer Research, 2021, 27, 2523-2532.	3.2	17
44	Validation of a methylated DNA marker panel for the nonendoscopic detection of Barrettâ€™s esophagus in a multisite case-control study. Gastrointestinal Endoscopy, 2021, 94, 498-505.	0.5	17
45	Stool DNA testing for cancer surveillance in inflammatory bowel disease: an early view. Therapeutic Advances in Gastroenterology, 2013, 6, 371-380.	1.4	16
46	Randomized Phase II Trial of Polyphenon E versus Placebo in Patients at High Risk of Recurrent Colonic Neoplasia. Cancer Prevention Research, 2021, 14, 573-580.	0.7	16
47	Methylated Bone Morphogenetic Protein 3 (BMP3) Gene: Evaluation of Tumor Suppressor Function and Biomarker Potential in Biliary Cancer. Journal of Molecular Biomarkers & Diagnosis, 2013, 04, 1000145.	0.4	15
48	Early Adoption of a Multitarget Stool DNA Test for Colorectal Cancer Screening. Mayo Clinic Proceedings, 2017, 92, 726-733.	1.4	14
49	Intestinal and Nonintestinal Cancer Risks for Patients with Crohn's Disease. Gastroenterology Clinics of North America, 2017, 46, 515-529.	1.0	14
50	Stool-Based Tests for Colorectal Cancer Screening: Performance Benchmarks Lead to High Expected Efficacy. Current Gastroenterology Reports, 2020, 22, 32.	1.1	14
51	Assessment of extracellular vesicle isolation methods from human stool supernatant. Journal of Extracellular Vesicles, 2022, 11, e12208.	5.5	14
52	Stool DNA Screening for Colorectal Cancer. Journal of Clinical Gastroenterology, 2011, 45, 301-308.	1.1	13
53	Efficacy of Difluoromethylornithine and Aspirin for Treatment of Adenomas and Aberrant Crypt Foci in Patients with Prior Advanced Colorectal Neoplasms. Cancer Prevention Research, 2019, 12, 821-830.	0.7	13
54	Methylated Eyes Absent 4 (EYA4) Gene Promotor in Non-neoplastic Mucosa of Ulcerative Colitis Patients with Colorectal Cancer. Inflammatory Bowel Diseases, 2013, 19, 2079-2083.	0.9	12

#	Article	IF	Citations
55	Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1778-1787.e8.	2.4	12
56	The Combination of Patient-Reported Clinical Symptoms and an Endoscopic Score Correlates Well with Health-Related Quality of Life in Patients with Ulcerative Colitis. Journal of Clinical Medicine, 2019, 8, 1171.	1.0	10
57	Integrating Genome and Methylome Data to Identify Candidate DNA Methylation Biomarkers for Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2079-2087.	1.1	10
58	Methylated DNA markers for plasma detection of ovarian cancer: Discovery, validation, and clinical feasibility. Gynecologic Oncology, 2022, 165, 568-576.	0.6	10
59	Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study. Scandinavian Journal of Gastroenterology, 2018, 53, 273-278.	0.6	8
60	Colorectal Cancer Screening With the Multitarget Stool DNA Test. American Journal of Gastroenterology, 2020, 115, 1737-1740.	0.2	8
61	DNA Methylation Markers for Detection of Cholangiocarcinoma: Discovery, Validation, and Clinical Testing in Biliary Brushings and Plasma. Hepatology Communications, 2021, 5, 1448-1459.	2.0	8
62	109 Discovery of Novel DNA Methylation Markers for the Detection of Colorectal Neoplasia: Selection by Methylome-Wide Analysis. Gastroenterology, 2014, 146, S-30.	0.6	7
63	Methylated DNA Markers of Esophageal Squamous Cancer and Dysplasia: An International Study. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2642-2650.	1.1	7
64	Recent trends in colorectal cancer screening methods based on Medicare claims data. Current Medical Research and Opinion, 2021, 37, 605-607.	0.9	7
65	Comprehensive aptamer-based screen of 1317 proteins uncovers improved stool protein markers of colorectal cancer. Journal of Gastroenterology, 2021, 56, 659-672.	2.3	7
66	Multitarget Stool DNA for Average Risk Colorectal Cancer Screening. Gastrointestinal Endoscopy Clinics of North America, 2020, 30, 553-568.	0.6	7
67	Multicancer early detection test: Preclinical, translational, and clinical evidenceâ€“generation plan and provocative questions. Cancer, 2022, 128, 861-874.	2.0	7
68	A 1-Year Cross-sectional Inflammatory Bowel Disease Surveillance Colonoscopy Cohort Comparing High-definition White Light Endoscopy and Chromoendoscopy. Inflammatory Bowel Diseases, 2021, 27, 594-602.	0.9	6
69	Detection of Cholangiocarcinoma by Assay of Methylated DNA Markers in Plasma. Gastroenterology, 2017, 152, S1041-S1042.	0.6	5
70	Sa1042 MULTI-TARGET STOOL DNA TESTING ENRICHES DETECTION OF COLORECTAL NEOPLASIA BY COLONOSCOPY BUT YIELD IS INFLUENCED BY BASELINE POLYP DETECTION RATES. Gastrointestinal Endoscopy, 2019, 89, AB149-AB150.	0.5	5
71	325â€ƒNovel Multi-Target Stool DNA Marker Panel Yields Highly Accurate Detection of Colorectal Cancer and Premalignant Neoplasia. American Journal of Gastroenterology, 2019, 114, S191-S191.	0.2	5
72	Vulvar Crohn's Disease: Clinical Features and Outcomes. American Journal of Gastroenterology, 2021, 116, 2296-2299.	0.2	5

#	Article	IF	Citations
73	Abstract 712: Detection of lung cancer by assay of novel methylated DNA markers in plasma. Cancer Research, 2017, 77, 712-712.	0.4	5
74	769 Novel Methylated DNA Markers Predict Site of Gastrointestinal Cancer. Gastroenterology, 2013, 144, S-84.	0.6	4
75	Comparison of Tissue-Based Molecular Markers in Younger versus Older Patients with Colorectal Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1570-1576.	1.1	4
76	Methylated Eya4 Gene in Non-Neoplastic Mucosa of Ulcerative Colitis Patients With Colorectal Cancer: Evidence for a Field Effect. Gastroenterology, 2011, 140, S-348-S-349.	0.6	3
77	Su1340 Detection of Colorectal Cancer and Polyps in Patients With Inflammatory Bowel Disease by Novel Methylated Stool DNA Markers. Gastroenterology, 2014, 146, S-440-S-441.	0.6	3
78	393 - Multi-Site Gastrointestinal Cancer Detection by Stool DNA. Gastroenterology, 2018, 154, S-95.	0.6	3
79	Su1664 â€“ High Yield of Total and Right-Sided Colorectal Neoplasia by Multi-Target Stool Dna Testing in Average Risk Patients Irrespective of Prior Screening. Gastroenterology, 2019, 156, S-602-S-603.	0.6	3
80	Detection of Postcolonoscopy Colorectal Neoplasia by Multi-target Stool DNA. Clinical and Translational Gastroenterology, 2021, 12, e00375.	1.3	3
81	Algorithm for blood-based panel of methylated DNA and protein markers to detect early-stage hepatocellular carcinoma with high specificity.. Journal of Clinical Oncology, 2020, 38, 4577-4577.	0.8	3
82	Novel methylated DNA markers accurately discriminate Lynch syndrome associated colorectal neoplasia. Epigenomics, 2020, 12, 2173-2187.	1.0	3
83	307 Novel Methylated DNA Markers for the Detection of Colorectal Neoplasia in Lynch Syndrome. Gastroenterology, 2016, 150, S70.	0.6	2
84	372 - Detection of Esophageal Cancer by Assay of Novel Methylated DNA Markers in Plasma. Gastroenterology, 2018, 154, S-87.	0.6	2
85	Mo1748 - Validation of Novel Methylated DNA Markers for the Detection of Esophageal Squamous Cell Carcinoma and Dysplasia: Multi-National Tissue Study. Gastroenterology, 2018, 154, S-794-S-795.	0.6	2
86	Tu1015 â€“ Multi-Target Stool Dna Testing: Yield As a Function of Time Since Last Colonoscopy. Gastroenterology, 2019, 156, S-947-S-948.	0.6	2
87	Distinct Cutoff Values of Adalimumab Trough Levels Are Associated With Different Therapeutic Outcomes in Patients With Inflammatory Bowel Disease. Crohn's & Colitis 360, 2019, 1, .	0.5	2
88	273â€ƒMulti-Target DNA Aberrations in Sporadic Colorectal Cancer Tissues Do Not Differ Between Younger and Older Patients. American Journal of Gastroenterology, 2019, 114, S160-S160.	0.2	2
89	Editorial: Clarity and Caution in the Natural History of Low-Grade Dysplasia in Ulcerative Colitis. American Journal of Gastroenterology, 2015, 110, 1473-1474.	0.2	1
90	Sa1921 Molecular Detection of Colorectal Neoplasia: Do Markers That Target Acquired DNA Alterations in Sporadic Cases Also Discriminate Lynch Syndrome Cases?. Gastroenterology, 2015, 148, S-355.	0.6	1

#	Article	IF	Citations
91	Multi-Target Stool DNA Testing in Patients at Increased Risk for Colorectal Neoplasia Shows Similar Positive Predictive Value to Average Risk Patients. American Journal of Gastroenterology, 2018, 113, S162.	0.2	1
92	1078 â€“ Methylated Dna Markers Detect Esophageal Squamous Dysplasia in Mucosal Tissue and When Sampled by Nonendoscopic Esophageal Balloons: An Exploratory Study. Gastroenterology, 2019, 156, S-227-S-228.	0.6	1
93	Response to â€œColorectal Cancer Screening by Stool DNA Testing and Patient Emotional Healthâ€. American Journal of Gastroenterology, 2019, 114, 829-830.	0.2	1
94	Certolizumab Trough Levels and Antibodies in Crohn Disease: A Single-Center Experience. Crohn's & Colitis 360, 2021, 3, .	0.5	1
95	Response:. Gastrointestinal Endoscopy, 2019, 89, 444.	0.5	1
96	Impact of the Sessile Serrated Polyp Pathway on Predicted Colorectal Cancer Outcomes. , 2022, 1, 55-62.		1
97	Colorectal cancer is increased in chronic liver diseases: IsÂsurveillance the answer?. Gastrointestinal Endoscopy, 2017, 86, 105-106.	0.5	0
98	Reply. Clinical Gastroenterology and Hepatology, 2020, 18, 520-521.	2.4	0
99	Multicancer early detection: International summit to Clarify the Roadmap. Cancer, 2022, 128, 859-860.	2.0	0
100	Discovery and Validation of Methylated DNA Markers From Pancreatic Neuroendocrine Tumors. , 2022, 1, 409-416.		0
101	High Positive Predictive Value of Multi-Target Stool DNA After Aerodigestive Tract Radiotherapy. , 2022, , .		0
102	Tissue methylated DNA markers for sporadic pancreatic cancer are strongly associated with familial and genetically predisposed pancreatic cancer. Pancreatology, 2022, , .	0.5	0